LiverDCP: A Disease-Cell-Protein Framework for Multi-scale Modeling of Disease Biology

Abstract

Understanding how molecular interactions give rise to disease phenotypes across cellular contexts remains a central challenge in biomedical research. Here, we introduce a Disease-Cell-Protein (DCP) paradigm for modeling multi-scale disease biology, which jointly represents disease states, cellular composition, and protein interaction networks within a unified graph architecture. We instantiate this paradigm in the liver as LiverDCP by integrating LiverHomo, a harmonized single-cell atlas of liver diseases, with proteome-wide predicted protein-protein interactions to construct over 280 context-specific interactomes across diverse liver disease and cellular conditions. LiverDCP employs a multi-context representation learning strategy that enables joint training across hundreds of disease-cell environments, capturing shared interaction principles while preserving context-specific variation. LiverDCP incorporates pretrained protein sequence-derived features through a geometry-aware two-phase training scheme that preserves embedding structure while improving predictive performance. The resulting DCP protein embeddings reveal extensive rewiring of protein functional states across diseases, providing a transferable representation for downstream biomedical applications. Without GWAS supervision during representation learning, LiverDCP enables disease-risk gene classification and identifies cell types through which genetic risk may act. For therapeutic target discovery, LiverDCP recovers established Phase II+ MASH targets and prioritizes previously unrecognized candidates from the unannotated proteome, with 26 of the top 50 predictions showing independent PubMed evidence related to MASH biology. Context-specific interaction analysis further provides mechanistic hypotheses for less-characterized candidates. Together, these results establish DCP as a generalizable framework for connecting molecular interactions, cellular context, genetic risk, and therapeutic opportunities across complex diseases.